

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number
WO 02/12215 A1

(51) International Patent Classification⁷: C07D 305/14,
493/04, A61K 31/335, C07D 493/04, 317/00, 305/00

(21) International Application Number: PCT/EP01/08730

(22) International Filing Date: 27 July 2001 (27.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
MI2000A001869 10 August 2000 (10.08.2000) IT

(71) Applicant (for all designated States except US): INDENA
S.P.A. [IT/IT]; Viale Ortles, 12, I-20139 Milano (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PONTIROLI,
Alessandro [IT/IT]; Viale Ortles, 12, I-20139 Milano
(IT). BOMBARDELLI, Ezio [IT/IT]; Via Val di Sole, 22,
I-20141 Milano (IT).

(74) Agents: MINOJA, Fabrizio et al.; Bianchetti Bracco Mi-
noja S.r.l., Via Rossini, 8, I-20122 Milan (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 02/12215 A1

BEST AVAILABLE COPY

(54) Title: PROCESS FOR THE PREPARATION OF BACCATIN III DERIVATIVES

(57) Abstract: A process for the preparation of 14 β -hydroxy-1,4-carbonate-deacetyl baccatin III and intermediates useful for the preparation of novel taxan derivatives with antitumor activity are disclosed.

PROCESS FOR THE PREPARATION OF BACCATIN III DERIVATIVES

The present invention relates to novel intermediates useful in the synthesis of 14 β -hydroxy-1,14-carbonate-deacetylbaaccatin III derivatives, and to a process for the preparation thereof. The intermediates obtained with the process of the invention can be used in the preparation of novel taxan derivatives with antitumor activity.


Taxanes are one of the most important classes of antitumor agents developed in recent years. Paclitaxel is a complex diterpene isolated from the bark of *Taxus brevifolia* and is considered a "lead compound" for cancer therapy. Extensive research is at present being carried out for taxan derivatives having higher pharmacological activity and improved pharmacokinetic profile. A particular approach relates to the baccatin III derivatives variously modified with respect to the basic structure. Examples of said compounds are the 14 β -hydroxy baccatin III derivatives disclosed in US 5,705,508, WO 97/43291, WO 96/36622. At present, 14 β -hydroxy-1,14-carbonate-deacetylbaaccatin III derivatives are prepared starting from the 14 β -hydroxy-deacetylbaaccatin III precursor, which is a natural compound obtainable in small amounts by extraction of leaves of *Taxus wallichiana*, as disclosed in EP 559,019. There is strong need for novel intermediates or alternative processes to those commonly used, which allow to prepare 14 β -hydroxy-1,14-carbonate-deacetylbaaccatin III derivatives simply and effectively.

It has now been found that 14 β -hydroxy-1,14-carbonate-deacetylbaaccatin III can be prepared by means of a process using 10-deacetylbaaccatin III as starting compound which, contrary to 14 β -hydroxy-baccatin III, can be easily isolated in large amounts from *Taxus baccata* leaves.


Therefore, the present invention provides a process for the preparation of

14 β -hydroxy-1,14-carbonate-deacetylbaccatin III comprising the following steps:


1. protection of the hydroxy groups at the positions 7 and 10 of 10 deacetylbaccatin III:




- 5 wherein R and R₁ are selected from hydrogen, C₁-C₁₀ alkyl or aryl, C₁-C₁₀ alkyl- or aryl-carbonyl, trichloroacetyl, C₁-C₄ trialkylsilyl; preferably, when R and R₁ are the same, they are trichloroacetyl, whereas when they are different, preferably R is trichloroacetyl and R₁ is acetyl, or R is triethyl or trimethylsilyl and R₁ is acetyl;
- 10 2. two-step oxidation to give the derivative oxidised at the 13- position and hydroxylated at the 14- position:




3. carbonation of the vicinal hydroxyls at the 1- and 14- positions to give the 1,14-carbonate derivative:



4. reduction of the carbonyl at the 13- position:



5. removal of the protective groups at the 7- and 10- positions:



The procedures for the protection of the 7- and 10- hydroxyls are described by Holton et al., Tetrahedron Letters 39, (1998) 2883-2886. The selective protection of the hydroxyls of the starting compound deacetylbaccatin III is possible due to their different reactivity. In particular, the reactivity towards acylating, alkylating or silylating agents has been found to vary in the order C(7)-OH>C(10)-OH>C(13)-OH>C(1)-OH, therefore the groups at 7- and 10- can be selectively protected while keeping the hydroxyls at 1- and 13- free.

Furthermore, by changing the reaction conditions, it is possible to reverse the reactivity order of the hydroxyls at 7- and 10- thus allowing the differential substitution thereof. Examples of reactants and reaction conditions usable in the protection of the hydroxyls at 10- and 7- are reported in the above cited publication.


The oxidation step of the hydroxyl at the 13- position is achieved with manganese dioxide or bismuth dioxide in a solvent selected from acetonitrile, acetone or ethyl acetate/methylene chloride 9:1 mixtures, under vigorous stirring, preferably with manganese dioxide in acetonitrile or acetone. The reaction proceeds quickly to give the oxidised derivative at the 13- position, which can be recovered from the reaction medium, whereas a longer reaction yields the 13- oxidised and 14- hydroxylated derivative.

The subsequent carbonation step of the hydroxyls at the 1- and 14- positions is usually effected with phosgene or triphosgene in a methylene chloride/toluene mixture in the presence of pyridine. Subsequently, the resulting 1,14-carbonate derivative can be easily reduced at the 13- position to give the corresponding 13-hydroxy derivative. Said reduction takes place regioselectively on the carbonyl at 13- while the carbonyl at 9- remains unchanged, and stereoselectively, affording almost exclusively the 13- α isomer. This reaction is usually carried out with sodium borohydride in methanol and provides high yields. The last step consists in deprotecting the hydroxyls at the 7- and 10- positions to give the final product 14 β -hydroxy-1,14-carbonate deacetylaccatin III. The conditions and the reactants which can be used in the selective deprotection of the hydroxyls at 7- and 10- are described in Zheng et al., Tetrahedron Lett., 1995, 36, 2001, and in Datta et al., J. Org. Chem., 1995, 60, 761. The resulting final product is an extremely useful intermediate for the synthesis of a variety of taxan derivatives. As mentioned above, said intermediate was prepared until now starting from 14 β -hydroxy

baccatin III extracted from the leaves of *Taxus wallichiana* in low yields. The process of the present invention allows to prepare the same intermediate in high yields starting from a compound available in large amounts. Examples of compounds with antitumor activity which can be prepared starting from 14 β -hydroxy-1,14-carbonate deacetylbaccatin III are reported in US 5,705,508, WO 97/43291, WO 96/36622.

According to a preferred embodiment of the process of the invention, deacetylbaccatin III is reacted with trichloroacetyl chloride in methylene chloride in the presence of triethylamine and using N,N-dimethylaminopyridine (DMAP) in catalytic amounts. The use of trichloroacetate as protecting group proved to be very advantageous in the oxidation, carbonation and reduction steps according to the process of the invention. In particular, the 7,10-bis-trichloroacetate derivative, which is obtained in quantitative yields from the starting compound, after oxidation and carbonation is easily reduced at the 13-position with simultaneous deprotection of the trichloroacetic groups to give 14 β -hydroxy-1,14-carbonate-deacetylbaccatin III. The use of DMAP in catalytic amounts provides definite advantages from the industrial and environmental point of views, when considering that until now the acylations of this substrate were carried out in pyridine with consequent discharge problems of the residual solvent.

The following intermediates obtained according to the preferred embodiment described above are part of the present invention:



The following examples illustrate the invention in greater detail.

Example I

Preparation of 7,10-bistrichloroacetyl-10-deacetylbaecatin III.

First alternative:

5 4.77 ml of trichloroacetic anhydride (42.32 mmol) is added by drops to a solution of 10 g of 10-deacetylbaecatin III (18.4 mmol) in 125 ml of dry methylene chloride and 42 ml of pyridine. The reaction mixture is kept under stirring for three hours or anyway until completion of the reaction, checking by
10 TLC on silica gel using as eluent an n-hexane/ethyl acetate 1:1 mixture. After completion of the reaction, 5 ml of methanol are added to destroy the excess of trichloroacetic anhydride, then water is added. The organic phase is thoroughly washed with acidic water (HCl) to remove pyridine, whereas the remaining organic phase is dried over MgSO₄ and concentrated to dryness under vacuum, to obtain a pale yellow solid (17 g) which is crystallised from chloroform:
15 $[\alpha]_D -34^\circ$ (CH₂Cl₂ C5.8) IR (KBr) 3517, 1771, 1728, 1240, 981, 819, 787, 675 cm⁻¹;
¹H-NMR (200MH): δ 8.11 (Bz C), 7.46 (Bz, BB'), 6.50 (s, H-10), 5.72 (m, H-7 H-29, 5.02 (d, J = 8 Hz, H-5), 4.95 8m, H-13), 4.37 (d, J = 8 Hz, H-20a), 4.18 (d, J = 8 Hz, H-20b), 4.02 (d, J = 6 Hz, H-3), 2.32 (s, 4-Ac), 2.22 (s, H-18),
20 1.91 (s, H-19), 1.25 and 1.11 (s, H-16, H-17), 1.94 (m, H 14 α), 1.89 (m, H14 β).

Second alternative:

10-deacetylbaecatin III (10 g, 18.38 mmol) is suspended in CH₂Cl₂ (120 ml), added with DMAP (220 mg, 1.4 mmol, 0.1 eqv.) and cooled to 0°C
25 on ice bath. Et₃N (10.26 ml, 73.6 mmol, 4 eqv.) and immediately after, Cl₃CCOCl (4.12 ml, 36.8 mmol, 2 eqv.) are added under nitrogen stream in 5 min, keeping the temperature under 10°C. After completion of the addition, the mixture is left under stirring on ice bath for 15 min, then the bath is removed

and the reaction stirred at room temperature for 1 h. After 1 h the reaction is checked by TLC (AcOEt 2/n-hexane 3, Rf 10-DAB III = 0.05, Rf 7,10-bistrichloroacetyl -10-DAB III = 0,26) and added with Cl_3CCOCl (1 ml, 0.5 eqv.). Stirring is continued at r.t. for 10 min, then the reaction is poured into a
5 beaker containing 160 g of triturated ice and left under stirring until equilibrium at r.t. (about 1h). The aqueous phase is then separated and extracted with CH_2Cl_2 (3 x 40 ml). The combined organic phases are washed with 1N HCl (20 ml), then with a NaHCO_3 saturated solution (20 ml), dried over Na_2SO_4 and the solvent is evaporated off. Crude weight: 16.5 g. After
10 crystallisation from chloroform, the IR, ^1H -NMR and $[\alpha]_D$ spectra are consistent with those of the compound obtained using pyridine and trichloroacetic anhydride.

Example II

Oxidation at 13- and hydroxylation at 14- of 7,10-bistrichloroacetate
15 10-deacetylbaccatin III.

30 g of activated MnO_2 are added to a solution of 10-deacetylbaccatin III 7,10-bistrichloroacetate (3 g) in acetonitrile (40 ml), stirring the suspension with magnetic stirrer at room temperature and monitoring the progress of the reaction by TLC (petroleum ether-ethyl acetate 5:5; Rf of the starting material
20 about 0.31). After about one hour, the formation of the 13-dehydroderivative is completed (TLC analysis, Rf of the 13-dehydroderivative about 0.50). Stirring is then continued for about 72 hours, during which time the 13-dehydroderivative is slowly oxidised to the corresponding 14 β -hydroxy derivative (Rf about 0.36). The reaction mixture is filtered through Celite, and
25 the cake is repeatedly washed with ethyl acetate. The solvent is evaporated off and the residue is purified by column chromatography on silica gel (100 ml, eluent petroleum ether-ethyl acetate 7:3) to obtain 170 mg of the 13-dehydroderivative and 2.38 g of the 14 β -hydroxy-13-dehydroderivative.

13-dehydro-14 β -hydroxy-10-deacetylbaaccatin III, 7,10-bis trichloroacetate: white powder, m.p. 97°C; IR (KBr disc): 3440, 1780, 1767, 1736, 1686, 1267, 1232, 1103, 1010, 854 cm⁻¹;

¹H-NMR (200MHz, CDCl₃): δ 8.07 (Bz AA'), 7.60 (Bz, C), 7.49 (Bz, BB'), 6.52 (s, H-10), 5.92 (d, J = 6.7 Hz, H-2), 5.70 (br t, J = 8.0 Hz, H-7), 4.95 (br d, J = 8.2 Hz, H-5), 4.37 (d, J = 8.2 Hz, H-20a), 4.31 (d, J = 8.2 Hz, H-20b), 4.17 (s, H14), 4.02 (d, J = 6.7 Hz, H-3), 2.71 (m, H-6), 2.29 (s, OAc), 2.17 (s, OAc), 1.96 (s, H-18), 1.27, 1.01 (s, H-16, H-17 and H-19).

Example III

10 Oxidation/hydroxylation of 7-triethylsilylbaaccatin III

10 g of activated MnO₂ are added to a solution of 7-triethylsilylbaaccatin III (1.0 g) in acetonitrile (10 ml), stirring the suspension with magnetic stirrer at room temperature and monitoring the progress of the reaction by TLC (petroleum ether-ethyl acetate 6:4; R_f of the starting material about 0.25). After about two hours, the formation of the 13-dehydroderivative is completed (TLC analysis, R_f of the 13-dehydroderivative about 0.45). Stirring is then continued for about 188 hours, during which time further MnO₂ (10 g) is added. The 13-dehydroderivative is slowly oxidised to the corresponding 14 β -hydroxy derivative (R_f about 0.38). The reaction mixture is filtered through Celite, and the cake is washed with ethyl acetate. The solvent is evaporated off and the residue is purified by column chromatography on silica gel (40 ml, eluent petroleum ether-ethyl acetate 7:3) to obtain 126 mg of the 13-dehydroderivative, 479 mg (46%) of the 14 β -hydroxy-13-dehydroderivative and 189 mg of a mixture of both.

25 13-Dehydro-7-triethylsilylbaaccatin III, white powder, m.p. 168°C [α]_D²⁵ - 35 (CH₂Cl₂, C 0.67) IR (KBr) 3488, 1726, 1711, 1676, 1373, 1269, 1244, 1230, 1105 cm⁻¹; ¹H-NMR (200MH CDCl₃): δ 8.07 (Bz AA'), 7.60 (Bz, C), 7.49 (Bz, BB'), 6.59 (s, H-10), 5.69 (d, J = 6.9 Hz, H-2), 4.92 (d, J = 8.2 Hz, H-5), 4.48

(dd, $J = 10.6$ Hz, H-7), 4.33 (d, $J = 8.0$ Hz, H-20a), 4.12 (d, $J = 8.0$ Hz, H-20b), 3.91, (d, $J = 6.9$ Hz, H-3), 2.96 (d, $J = 20$ Hz, H-14a), 2.65 (d, $J = 20$ Hz, H-20b), 2.50 (m, H-6 α), 2.23 (s, OAc), 2.19 (s, OAc + H-18), 1.67, 1.28, 1.19 (s, H-16, H-17 and H-19), 0.19 (m, TES).

- 5 13-Dehydro-14 β -hydroxy-10-deacetylbaecatin III, 7,10-bis trichloroacetate: white powder, m.p. 153°C $[\alpha]_{\text{D}}^{25} + 20$ (CH_2Cl_2 , C 0.75) IR (KBr) 3431, 1723, 1692, 1371, 1269, 1242, 1223, 1096 cm^{-1} ; $^1\text{H-NMR}$ (500MH CDCl_3): δ 8.06 (Bz AA'), 7.60 (Bz, C), 7.48 (Bz, BB'), 6.51 (s, H-10), 5.88 (d, $J = 6.9$ Hz, H-2), 4.90 (d, $J = 8.2$ Hz, H-5), 4.47 (dd, $J = 10.6$ 7 Hz, H-7), 4.30 (d, $J = 8$ Hz, H-20a), 4.28 (d, $J = 8.2$ Hz, H-20b), 4.13 (br d, $J = 2$ Hz, H-14), 3.84 (d, $J = 6.9$ Hz, H-3), 3.69 (br d, $J = 2$ Hz, 14-OH), 3.62 (s, 1-OH), 2.52 (m, H-6 α), 2.24 (s, OAc), 2.21 (s, OAc), 2.11 (s, H-18), 1.92 (m, H-6 β), 1.74, 1.56, 1.28 (s, -h-16, H-17 and H-19), 0.94 (m, TES), 0.59 (m, TES). HRNS: 714.3092 (calculated for $\text{C}_{37}\text{H}_{50}\text{O}_{12}\text{Si}$ 714.3092).
- 10

15 Example IV

Oxidation/hydroxylation of 7-triethylsilylbaecatin III

- 10 g of activated MnO_2 are added to a solution of 7-triethylsilylbaecatin III (1.0 g) in acetonitrile (10 ml), with stirring at room temperature and monitoring the progress of the reaction by TLC (petroleum ether-ethyl acetate 6:4; R_f of the starting material about 0.25). After about two hours, the formation of the 13-dehydroderivative is completed (TLC analysis, R_f of the 13-dehydroderivative about 0.45). Stirring is then continued for about 188 hours, during which time further MnO_2 (10 g) is added. The 13-dehydroderivative is slowly oxidised to the corresponding 14 β -hydroxy derivative (R_f about 0.38). The reaction mixture is filtered through Celite, and the cake is washed with ethyl acetate. The solvent is evaporated off and the residue is purified by column chromatography on silica gel (40 ml, eluent petroleum ether-ethyl acetate 7:3) to obtain 126 mg of the 13-
- 20
- 25

dehydroderivative, 479 mg (46%) of the 14 β -hydroxy-13-dehydroderivative and 189 mg of a mixture of both.

13-Dehydro-7-triethylsilylbaccatin III. white powder, m.p. 210°C [α]_D²⁵ - 48 (CH₂Cl₂, C 0.50) IR (KBr) 3478, 1728, 1676, 1373, 1271, 1240, 1071, 1026 cm⁻¹; ¹H-NMR (200MH CDCl₃): δ 8.07 (Bz AA'), 7.64 (Bz, C), 7.50 (Bz, BB'), 6.46 (s, H-10), 5.70 (d, J = 6.9 Hz, H-2), 4.95 (d, J = 8.2 Hz, H-5), 4.51 (dd, J = 10.7 Hz, H-7), 4.32 (d, J = 8.4 Hz, H-20a), 4.14 (d, J = 8.4 Hz, H-20b), 3.92, (d, J = 6.9 Hz, H-3), 2.99 (d, J = 20 Hz, H-14a), 2.68 (d, J = 20 Hz, H-14b), 2.56 (m, H-6 α), 2.29 (s, OAc), 2.18 (s, OAc), 2.08 (s, H-18), 1.68, 1.29, 1.20 (s, H-16, H-17 and H-19), 0.19.

13-Dehydro-14 β -hydroxy-7-triethylsilylbaccatin III: white powder, m.p. 220°C [α]_D²⁵ + 19 (CH₂Cl₂, C 0.42) IR (KBr) 3568, 1710, 1719, 1686, 1372, 1282, 1240, 1219, 1073 cm⁻¹; ¹H-NMR (200MH CDCl₃): δ 8.09 (Bz AA'), 7.60 (Bz, C), 7.51 (Bz, BB'), 6.39 (s, H-10), 5.89 (d, J = 6.9 Hz, H-2), 4.94 (d, J = 8.2 Hz, H-5), 4.47 (dd, J = 10.7 Hz, H-7), 4.31 (br s, -H-20a + H-20b), 4.15 (s, H-14), 3.69 (d, J = 6.9 Hz, H-3), 2.29 (s, OAc), 2.16 (s, H-18), 2.14 (s, OAc), 1.74, 1.21, 1.10 (s, H-16, H-17 and H-19), HRMS: 600.6112 0.19 (calculated for C₃₁H₃₆O₁₂Si 600.6103).

Example V

20 Preparation of 1,14-carbonate-13-dehydro-7-tes-baccatin III.

A solution of 13-dehydro-14 β -hydroxy-7-triethylsilylbaccatin III (124 mg, 1.17 mMol) in CH₂Cl₂ (1 ml) and pyridine (0.56 ml, 6.8 mMol, 20 mol. equiv.) is added drop by drop in 5 min to a solution of phosgene (1.8 ml of a 20% solution in toluene, 3.4 mMol, 20 mol. equiv.) in CH₂Cl₂ (2 ml). The mixture is stirred at room temperature for 1 hour and subsequently the excess of phosgene is neutralised with a NaHCO₃ saturated solution and extracted with CH₂Cl₂. The organic phase is washed with a NaHCO₃ saturated solution, brine, and dried (Na₂SO₄). The solvent is evaporated off to yield a reddish residue,

which is purified on a small silica gel column (about 5 ml, eluent hexane/ethyl acetate 8:2) to obtain 118 mg (92%) of the carbonate. When the reaction is carried out with triethylamine as base without the reverse addition, mixture of 1,14-carbonate and 2-debenzoyl-1,2-carbonate-14 benzoate (about 1 : 15) is
5 obtained.

13-Dehydro-14 β -hydroxy-7-triethylsilylbaccatin III 1,14-carbonate, white powder, m.p. 153°C $[\alpha]_D^{25} + 23$ (CH₂Cl₂, C 0.75) IR (KBr) No. of band OH 1834, 1734, 1709, 1373, 1242, 1225, 1088, 1057 cm⁻¹; ¹H-NMR (200MH CDCl₃): δ 7.99 (Bz AA'), 7.60 (Bz, C), 7.48 (Bz, BB'), 6.51 (s, H-10), 6.12 (d, J = 6.9 Hz, H-2), 4.90 (d, J = 8.2 Hz, H-5), 4.78 (s, H-14), 4.44 (dd, J = 10.7 Hz, H-7), 4.34 (d, J = 8 Hz, H-20a), 4.19 (d, J = 8.2 Hz, H-20b), 3.80 (d, J = 6.9 Hz, H-3), 2.50 (m, H-6 α), 2.23 (s, OAc), 2.22 (s, OAc), 2.19 (s, H-18), 1.92 (m, H-6 β), 1.72, 1.39, 1.26 (s, -H-16, H-17 and H-19), 0.90 (m, TES), 0.56 (m, TES). HRNS: 740.2851 (calculated for C₃₈H₄₈O₁₃Si 740.2864).

15 13-Dehydro-14 β -hydroxybaccatin III 1,14-carbonate, white powder 240°C $[\alpha]_D^{25} - 2.5$ (CH₂Cl₂, C 0.4) IR (KBr) 3539, 1831, 1736, 1240, 1088, 1068, 1057, 1024 cm⁻¹; ¹H-NMR (200MH CDCl₃): δ 7.98 (Bz AA'), 7.61 (Bz, C), 7.50 (Bz, BB'), 6.39 (s, H-10), 6.14 (d, J = 6.9 Hz, H-2), 4.98 (d, J = 8.2 Hz, H-5), 4.80 (s, H-14), 4.43 (dd, J = 10.7 Hz, H-7), 4.35 (d, J = 8 Hz, H-20a), 4.24 (d, J = 8.2 Hz, H-20b), 3.80 (d, J = 6.9 Hz, H-3), 2.50 (m, H-6 α), 2.30 (s, OAc), 2.20 (s, OAc), 2.15 (s, H-18), 1.90 (m, H-6 β), 1.74, 1.34, 1.25 (s, H-16, H-17 and H-19), HRMS: 626.2005 (calculated for C₃₃H₃₄O₁ 626.1999).

Example VI

Preparation of 1,14-carbonate-7-O-triethylsilyl baccatin III

25 An excess of NaBH₄ (about 20 mg) is added in small portions to a solution of 13-dehydro-14 β -hydroxy-7-triethylsilylbaccatin III 1,14-carbonate (50 mg) in methanol (5 ml). After 30 min., the reaction mixture is added with saturated NH₄Cl, extracted with ethyl acetate, washed with brine, dried over

Na₂SO₄ and the solvent is removed, to give a residue which is purified by column chromatography in silica gel (about 5 ml, elution with hexane-ethyl acetate 8:2) to obtain 35 mg of the 13 α -hydroxy derivative and 9 mg of the 13 β -hydroxy derivative.

- 5 14 β -Hydroxy-7-triethylsilylbaccatin III 1,14-carbonate [α]_D²⁵ -35 (CH₂Cl₂, C 0.60) IR (KBr) 3054, 1819, 1736, 1603, 1371, 1261, 1238, 1090, 1069, cm⁻¹; ¹H-NMR (200MH CDCl₃): δ 8.06 (Bz AA'), 7.65 (Bz, C), 7.50 (Bz, BB'), 6.47 (s, H-10), 6.12 (d, J = 6.9 Hz, H-2), 5.05 (br d, J = 5.5 Hz, H-13), 4.98 (br d, J = 9 Hz, H-5), 4.83 (d, J = 5 Hz, H-14), 4.50 (dd, J = 10.7 Hz, H-7), 4.34 (d, J = 8 Hz, H-20a), 4.23 (d, J = 8 Hz, H-20b), 3.75 (d, J = 6.9 Hz, H-3), 2.56 (m, H-6 α), 2.34 (s, OAc), 2.22 (s, OAc), 1.78 (m, H-6 β), 1.35 (s, H-18), 1.75, 1.18, 0.95 (s, -H-16, H-17 and H-19), 0.90 (m, TES), 0.62 (m, TES).

- 10 14 β -Hydroxy-7-triethylsilyl-13-epibaccatin III 1,14-carbonate, amorphous [α]_D²⁵ - 13 (CH₂Cl₂, C 0.60) IR (KBr) 3630, 1825, 1734, 1603, 1375, 1262, 15 1091, 1071, 1049 cm⁻¹; ¹H-NMR (200MH CDCl₃): δ 8.01 (Bz AA'), 7.63 (Bz, C), 7.48 (Bz, BB'), 6.44 (s, H-10), 6.12 (d, J = 7.2 Hz, H-2), 4.90 (br d, J = 9 Hz, H-5), 4.81 (d, J = 8 Hz, H-14), 4.48 (br, J = 8, H-13), 4.50 (dd, J = 10, 7 Hz, H-7), 4.41 (d, J = 8 Hz, H-20a), 4.31 (d, J = 8 Hz, H-20b), 3.68 (d, J = 7.2 Hz, H-3), 2.60 (m, H-6 α), 2.32 (s, OAc), 2.26 (s, H-18), 2.21 (s, OAc), 1.80 20 (m, H-6 β), 1.72, 1.43, 1.27 (s, -H-16, H-17 and H-19), 0.93 (m, TES), 0.61 (m, TES).

Example VII

Preparation of 13-dehydro-14 β -hydroxy-7,10-bistrichloroacetyl-baccatin III 1,14-carbonate.

- 25 A solution of 13-dehydro-14 β -hydroxy-7,10-bistrichloroacetyl-baccatin III (200 mg) in CH₂Cl₂ (2 ml) and pyridine (1.12 ml, 20 equiv.) is added in 5 min with a solution of phosgene (20% in toluene, 3.6 ml, 20 equiv.) in CH₂Cl₂ (2 ml). The mixture is stirred at r.t. for 1 h, then the excess of phosgene is

neutralised with a NaHCO_3 saturated solution (3 ml). The mixture is extracted with CH_2Cl_2 , the organic phase is washed with a NaHCO_3 saturated solution, then with a NaCl saturated solution and dried over Na_2SO_4 . After removal of the solvent, the residue is purified by chromatography on a silica gel column (eluent hexane/AcOEt 9:1) to obtain 175 mg (89%) of the carbonate.

13-Dehydro-14 β -hydroxy-7,10-bistrichloroacetyl-baccatin III 1,14-carbonate, amorphous white solid. IR (KBr) 1834, 1771, 1735, 1709, 1232, 1103, 1010, 854 cm^{-1} .

^1H NMR (200 MHz, CDCl_3): δ = 8.03 (Bz AA'), 7.60 (Bz, C), 7.50 (Bz, BB'), 6.52 (s, H-10), 5.92 (d, J = 6.7 Hz, H-2), 5.70 (br t, J = 8.0 Hz, H-7), 4.95 (br d, J = 8.2 Hz, H-20b), 4.77 (s, H-14), 4.02 (d, J = 6.7 Hz, H-3), 2.71 (m, H-6), 2.29 (s, OAc), 1.96 (s, H-18), 1.27 - 1.01 (m, H-16, H-17, H-19).

Example VIII

Preparation of 14 β -hydroxy-10-deacetyl baccatin III 1,14-carbonate.

A solution of 13-dehydro-14 β -hydroxy-7,10-bistrichloroacetyl-baccatin III 1,14-carbonate (500 mg) in MeOH (8 ml) is cooled to 0°C on ice bath and added with solid NaBH_4 (44 mg) in 5 min. The mixture is stirred at r.t. for 1 h, then cooled to 0°C . Acetone is added (2 ml) in 5 min, the mixture is concentrated, then added with AcOEt (10 ml) and filtered through Celite. The clear solution is washed with a NaCl saturated solution and dried over Na_2SO_4 . The solvent is evaporated off to give a residue (4.5:1 mixture of C13 epimers) which is purified by chromatography on a silica gel column (eluent hexane/AcOEt 1:1) to obtain 251 mg of the 13 β epimer and 55 mg of the 13 α epimer (88% total) of the deprotected carbonate.

13 α -14 β -hydroxy-10-deacetyl baccatin III 1,14-carbonate. amorphous white solid. IR (KBr): 3520 (OH), 1834, 1709, 1232, 1103, 1010, 854 cm^{-1} .

^1H NMR (200 MHz, CDCl_3): δ = 8.03 (Bz AA'), 7.60 (Bz, C), 7.50 (Bz, BB'), 6.27 (s, H-10), 5.92 (d, J = 6.7 Hz, H-2), 4.95 (br d, J = 8.2 Hz, H-20b), 4.85

(m, H-13), 4.77 (s, H-14), 4.42 (br t, $J = 8.0$ Hz, H-7), 4.02 (d, $J = 6.7$ Hz, H-3), 2.71 (m, H-6), 2.29 (s, OAc), 1.96 (s, H-18), 1.27 - 1.01 (m, H-16, H-17, H-19).


13 α -14 β -hydroxy-10-deacetylbaecatin III 1,14-carbonate, amorphous white
5 solid. IR (KBr): 3520 (OH), 1834, 1709, 1232, 1103, 1010, 854 cm^{-1} .

^1H NMR (200 MHz, CDCl_3): $\delta = 8.03$ (Bz AA'), 7.60 (Bz, C), 7.50 (Bz, BB'),
6.27 (s, H-10), 5.92 (d, $J = 6.7$ Hz, H-2), 4.95 (br d, $J = 8.2$ Hz, H-20b), 4.80
(m, H-13), 4.77 (s, H-14), 4.42 (br t, $J = 8.0$ Hz, H-7), 4.02 (d, $J = 6.7$ Hz, H-3),
2.71 (m, H-6), 2.29 (s, OAc), 1.96 (s, H-18), 1.27 - 1.01 (m, H-16, H-17, H-19).
10

CLAIMS


1. A process for the preparation of 14 β -hydroxy-1,14-carbonate-deacetylbaaccatin III, which comprises the following, steps:

- 5 a. protection of the hydroxyls at the 7- and 10- positions of 10-deacetylbaaccatin III:




wherein R and R₁ are selected from hydrogen, C₁-C₁₀ alkyl or aryl, C₁-C₁₀ alkyl- or aryl-carbonyl, trichloroacetyl, C₁-C₄ trialkylsilyl; preferably, when R and R₁ are the same, they are trichloroacetyl, whereas when they are different, preferably R is trichloroacetyl and R₁ is acetyl, or R is triethyl or trimethylsilyl and R₁ is acetyl;


- b. two-step oxidation to give the derivative oxidised to carbonyl at the 13- position and hydroxylated at the 14- position:




- c. carbonation of the vicinal hydroxyls at the 1- and 14- positions to give the 1,14-carbonate derivative:



d. reduction of the carbonyl at the 13- position:



e. removal of the protective groups at the 7- and 10- positions:



2. A process as claimed in claim 1 wherein R and R₁ are the same and are
5 trichloroacetyl, or R and R₁ are different and then R is trichloroacetyl and R₁ is acetyl, or R is triethyl or trimethylsilyl and R₁ is acetyl.
3. A process as claimed in claim 2, in which R and R₁ are trichloroacetyl.
4. A process as claimed in claim 3, in which the protection step of the
hydroxyls at the 7- and 10- positions is carried out with trichloroacetyl chloride
10 in methylene chloride in the presence of triethylamine and of catalytic amounts

of N,N-dimethylaminopyridine.

5. A process as claimed in claims 1-4, in which the oxidation of the hydroxyl at the 13- position and the hydroxylation at the 14- position are effected with manganese dioxide or bismuth dioxide in a solvent selected from acetonitrile, acetone or ethyl acetate/ methylene chloride mixtures.
6. A process as claimed in claims 1-5, in which the carbonation step of the hydroxyls at the 1- and 14- positions is effected with phosgene in methylene chloride/toluene mixture in the presence of pyridine.
7. A process as claimed in claims 1-6, in which the reduction step to 13-hydroxy is effected with sodium borohydride in methanol.
8. The following reaction intermediates:
- 7,10-bistrichloroacetyl-10-deacetylbaaccatin III,
 - 13-dehydro-14 β -hydroxy-10-deacetylbaaccatin III,
 - 13-dehydro-14 β -hydroxy-7-triethylsilylbaaccatin III,
 - 1,14-carbonate-13-dehydro-7-triethylsilylbaaccatin III,
 - 1,14-carbonate-7-O-triethylsilylbaaccatin III,
 - 13-dehydro-14 β -hydroxy-7,10-bistrichloroacetyl-baaccatin III
 - 1,14-carbonate.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP 01/08730

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D305/14 C07D493/04 A61K31/335 //(C07D493/04, 317:00, 305:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 750 562 A (GABETTA BRUNO ET AL) 12 May 1998 (1998-05-12) column 3	8
X	US 5 698 712 A (GABETTA BRUNO ET AL) 16 December 1997 (1997-12-16) example 7	8
P, X	WO 00 52003 A (INDENA SPA ; BOMBARDELLI EZIO (IT)) 8 September 2000 (2000-09-08) compound III	8
A	WO 96 36622 A (INDENA SPA ; BOMBARDELLI EZIO (IT)) 21 November 1996 (1996-11-21) cited in the application the whole document	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

1 November 2001

Date of mailing of the international search report

09/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fritz, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/08730

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5750562	A	12-05-1998	IT MI950533 A1	17-09-1996
			AT 193286 T	15-06-2000
			AU 705923 B2	03-06-1999
			AU 4832096 A	08-10-1996
			CA 2215682 A1	26-09-1996
			DE 69608548 D1	29-06-2000
			DE 69608548 T2	01-02-2001
			DK 815095 T3	07-08-2000
			WO 9629321 A1	26-09-1996
			EP 0815095 A1	07-01-1998
			ES 2146389 T3	01-08-2000
			GR 3033742 T3	31-10-2000
			HK 1005242 A1	20-10-2000
			JP 11502206 T	23-02-1999
			NO 974266 A	16-09-1997
			PT 815095 T	29-09-2000
			US 5973163 A	26-10-1999
US 5698712	A	16-12-1997	IT 1254517 B	25-09-1995
			US 5453520 A	26-09-1995
			AT 184599 T	15-10-1999
			CA 2091001 A1	07-09-1993
			CN 1076695 A , B	29-09-1993
			CZ 9300336 A3	19-01-1994
			DE 69326369 D1	21-10-1999
			DE 69326369 T2	23-03-2000
			DK 559019 T3	27-03-2000
			EP 0559019 A1	08-09-1993
			ES 2136096 T3	16-11-1999
			FI 930978 A	07-09-1993
			GR 3031280 T3	31-12-1999
			HK 1011686 A1	20-04-2000
			HU 64317 A2	28-12-1993
			HU 9500594 A3	30-10-1995
			JP 2708346 B2	04-02-1998
			JP 6009599 A	18-01-1994
			KR 255525 B1	01-05-2000
			NO 305080 B1	29-03-1999
WO 0052003	A	08-09-2000	PL 297940 A1	15-11-1993
			SK 15293 A3	08-12-1993
			US 5264591 A	23-11-1993
			AU 3806000 A	21-09-2000
			WO 0052003 A1	08-09-2000
WO 9636622	A	21-11-1996	IT MI951022 A1	19-11-1996
			AT 195312 T	15-08-2000
			AU 696366 B2	10-09-1998
			AU 5893996 A	29-11-1996
			CA 2212357 A1	21-11-1996
			DE 69609723 D1	14-09-2000
			DE 69609723 T2	14-12-2000
			DK 862563 T3	30-10-2000
			WO 9636622 A1	21-11-1996
			EP 0862563 A1	09-09-1998
			ES 2148766 T3	16-10-2000
			GR 3034321 T3	29-12-2000
			HK 1011537 A1	01-12-2000

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 01/08730

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9636622	A	JP 11505232 T	18-05-1999
		NO 973545 A	17-11-1997
		PT 862563 T	30-11-2000
		US 5917056 A	29-06-1999

THIS PAGE BLANK (USPTO)